Novo Nordisk's Ozempic has become a billion-dollar sensation in weight loss, originally intended as a diabetes treatment. It is now a key revenue source.
The company has faced regulatory scrutiny, including fines and lawsuits, challenging its practices in marketing and pricing in the weight loss drug market.
Collection
[
|
...
]